You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君实生物-B(01877.HK):上半年收入3.09亿元 研发投入3.69亿元
格隆汇 08-29 22:37

格隆汇8月29日丨君实生物-B(01877.HK)发布中期业绩,截至2019年6月30日止6个月,公司持续经营业务实现销售收入总额3.09亿元人民币(下同),毛利2.69亿元,公司拥有人应占期内亏损2.89亿元,基本每股亏损0.37元。

2019年上半年,公司销售收入总额达3.09亿元,其中约3.08亿万元源于特瑞普利单抗销量攀升,其毛利为87%。公司恪守承诺,持续投入研究及开发,于2019年上半年,研发开支为3.69亿元,较2018年上半年增加69%,关键临床试验取得重大进展。

此外,销售及分销开支为1.11亿元,主要由于2019年初特瑞普利单抗商业化所致。2019年上半年,全面开支总额为2.89亿元,较2018年上半年的2.67亿元略微增加,主要由于来自特瑞普利单抗销售产生的溢利,但被持续增长的研发开支,以及行政开支增加所抵销所致。

2019年上半年,投资活动所用现金净额为4.37亿元,主要由于建设临港生产基地的投入所致,临港生产基地的建成投产将大幅提升公司现有的产能。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account